When autologous GM-CSF tumor vaccines were tested in combination with post-resection adjuvant 5-FU-based chemoradiotherapy in a phase II clinical trial with each patient receiving 5 × 108 vaccine cells, median disease-free survival was found to be 17.3 months (NCT00084383) [193], longer than historical controls. This evidence concerns the gene CSF2 and neoplasm.